Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Guided Therapeutics (GTHP) Enterprise Value (2016 - 2025)

Guided Therapeutics' Enterprise Value history spans 16 years, with the latest figure at -$87000.0 for Q3 2025.

  • For Q3 2025, Enterprise Value rose 55.15% year-over-year to -$87000.0; the TTM value through Sep 2025 reached -$87000.0, up 55.15%, while the annual FY2024 figure was -$388000.0, 34.35% up from the prior year.
  • Enterprise Value for Q3 2025 was -$87000.0 at Guided Therapeutics, up from -$185000.0 in the prior quarter.
  • Across five years, Enterprise Value topped out at -$87000.0 in Q3 2025 and bottomed at -$2.7 million in Q3 2022.
  • The 5-year median for Enterprise Value is -$591000.0 (2023), against an average of -$828421.1.
  • The largest annual shift saw Enterprise Value tumbled 5838.1% in 2021 before it surged 79.75% in 2024.
  • A 5-year view of Enterprise Value shows it stood at -$643000.0 in 2021, then tumbled by 259.72% to -$2.3 million in 2022, then surged by 74.45% to -$591000.0 in 2023, then surged by 34.35% to -$388000.0 in 2024, then skyrocketed by 77.58% to -$87000.0 in 2025.
  • Per Business Quant, the three most recent readings for GTHP's Enterprise Value are -$87000.0 (Q3 2025), -$185000.0 (Q2 2025), and -$115000.0 (Q1 2025).